Fulcrum Therapeutics (FULC) Invested Capital (2019 - 2025)
Fulcrum Therapeutics (FULC) has disclosed Invested Capital for 7 consecutive years, with $349.0 million as the latest value for Q4 2025.
- On a quarterly basis, Invested Capital rose 43.6% to $349.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $349.0 million, a 43.6% increase, with the full-year FY2025 number at $349.0 million, up 43.6% from a year prior.
- Invested Capital was $349.0 million for Q4 2025 at Fulcrum Therapeutics, up from $198.4 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $349.0 million in Q4 2025 to a low of $110.9 million in Q2 2021.
- A 5-year average of $224.6 million and a median of $225.0 million in 2022 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: surged 122.25% in 2021, then decreased 27.9% in 2024.
- Fulcrum Therapeutics' Invested Capital stood at $211.5 million in 2021, then dropped by 5.95% to $198.9 million in 2022, then increased by 18.22% to $235.2 million in 2023, then rose by 3.33% to $243.0 million in 2024, then skyrocketed by 43.6% to $349.0 million in 2025.
- Per Business Quant, the three most recent readings for FULC's Invested Capital are $349.0 million (Q4 2025), $198.4 million (Q3 2025), and $214.4 million (Q2 2025).